|
|
GnRH-a on Endometriosis and the Level of Histone H3K4 Methylation in Patients with Endometriosis |
JIN Fengyu |
Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University, Beijing 100026, China |
|
|
Abstract Objective: To investigate the efficacy of gonadotropin releasing hormone agonist (GnRH-a) in the treatment of endometriosis (EMS) and the effect on the level of histone 3 lysine 4 (H3K4) methylation in patients with endometriosis. Method: 96 cases of EMS patients admitted in our hospital from January 2015 to June 2016 were selected as the study subjects. All patients were treated with elective laparoscopic surgery and were randomly divided into the observation group and the control group, 48 cases in each group. The control group was treated with mifepristone after surgery, and the observation group was additionally treated with GnRH-1. The effective rate of treatment, pregnancy rate, recurrence rate, levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were compared between the two groups. The positive rate of anti-endometrial antibody (EMAB), positive rate of angiopoietin-2 (Ang-2), H3K4 methylation, tissue inhibitor of metalloproteinase-1(TIMP-1), vascular endothelial growth factor (VEGF) and glycoprotein 125 (CA125) in the two groups were analyzed, and adverse reactions were observed. Results: The total effective rate of treatment and the pregnancy ratein the observation group were significantly higher than those in the control group (97.92% and 29.17% vs 85.42% and 10.42%) (P< 0.05), and the half-year recurrence rate was lower than that in the control group (2.08% vs 16.67%) (P< 0.05). After treatment, levels of serum FSH, LH and E2 were significantly lower in the observation group than the control group (P< 0.05). After treatment, the positive rates of EMAB and Ang-2 in the observation group were lower than those in the control group, while H3K4 methylationwas higher than that in the control group (P< 0.05). After treatment, the levels of serum TIMP-1, VEGF and CA125 were significantly lower in the observation group than the control group (P< 0.05). There was no significant difference between the two groups in the incidence of adverse reactions (10.42% vs 6.25%) (P > 0.05). Conclusion: GnRH-a is better than mifepristone in the treatment of EMS. It can significantly reduce the levels of hormone, EMAB, Ang-2, serum TIMP-1, VEGF and CA125 level and the recurrence rate. It also can improve the H3K4 methylation level and pregnancy rate, with high safety.
|
|
|
|
|
[1] 王红,洪莉.腹腔镜联合GnRH-a对子宫内膜异位症患者VEGF、IL-18及TNF-α的影响分析[J].河北医药,2016,38(8):1125~1128.
[2] 李莉,蒋睿,马彩玲,等.CT对卵巢子宫内膜异位囊肿的诊断及鉴别诊断价值分析[J].中国CT和MRI杂志,2016,14(8):28~30.
[3] 彭二玄,杨欣,梁旭东.GnRH-a治疗子宫内膜异位症“点火效应”导致严重痛经一例[J].中国妇产科临床,2015,16(2):183~184.
[4] 史晨霞,薛涛涛,赵秀娟,等.酿酒酵母组蛋白H3K14乙酰化对H3K4三甲基化的影响[J].信阳师范学院学报(自然科学版),2016,29(2):200~203.
[5] 中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志,2015,50(3):161~169.
[6] 卢红,卢蓉,陆月梅,等.腹腔镜下子宫内膜异位症生育指数的生育能力评估的作用[J].湖南师范大学学报(医学版),2015,12(1):45~48.
[7] 王君,李霞,原迪,等.GnRH-a对子宫内膜异位症患者血清CA125、EMAB及RANTES的影响[J].现代生物医学进展,2015,15(34):6686~6688,6745.
[8] 胡京辉,刘金炜.腹腔镜联合孕三烯酮治疗卵巢子宫内膜异位囊肿的临床疗效[J].中华全科医学,2015,13(4):609~610.
[9] 徐安利,张素芹,陈琪,等.DNA甲基化对子宫内膜异位症(EMs)的作用及其调控机制[J].现代生物医学进展,2014,14(23):4574~4577.
[10] 邹宗楷,黄轶群,沈洪武,等.套细胞淋巴瘤中LSD1、H3K4me1、H3K4me2蛋白表达及临床意义[J].临床与实验病理学杂志,2015,31(12):1402~1404.
[11] 秦娟,宋国林,刘卿,等.GnRH-a与去氧孕烯炔雌醇片对子宫内膜异位症血管生成素-2的影响[J].中国妇产科临床,2016,17(4):363~365.
[12] 詹润芳.GnRH-a联合腹腔镜保守性手术治疗Ⅲ~Ⅳ期子宫内膜异位症的疗效及复发因素分析[J].医学临床研究,2016,33(2):238~241. |
|
|
|